Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317751 | 0.98 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL1050445 | 0.93 | PPARG (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL28811427 | 0.93 | AKR1B1 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR | |
| SCHEMBL5317815 | 0.92 | AKR1B1 (0.43) | PPARGAKR1B1TBXAS1PPARDPPARA | |
| SCHEMBL5272164 | 0.92 | TBXAS1 (0.42) | CYP1A2CYP3A4CYP2D6CYP2C9PPARG | |
| SCHEMBL5316058 | 0.91 | KMO (0.44) | PPARGAKR1B1TBXAS1PPARDPPARA | |
| SCHEMBL5320470 | 0.90 | TBXAS1 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C9PPARG | |
| SCHEMBL5319300 | 0.90 | AKR1B1 (0.45) | PPARGAKR1B1TBXAS1PPARDPPARA | |
| SCHEMBL5318259 | 0.89 | KMO (0.46) | PPARGAKR1B1TBXAS1PPARDPPARA | |
| SCHEMBL5322190 | 0.88 | NPSR1 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502624-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | THE UNIVERSITY OF KANSAS (US) | 2012-09-26 | — | — | EP | claimed |
| EP-1786424-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | The University of Kansas (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006023704-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | UNIVERSITY OF KANSAS (US) | 2006-03-02 | — | — | WO | claimed |
| CN-104011027-A | Use of lonidamine analogs for fertility regulation | UNIV KANSAS | 2014-08-27 | — | — | CN | disclosed |
| EP-2502624-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | THE UNIVERSITY OF KANSAS (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2502624-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | THE UNIVERSITY OF KANSAS (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-1786424-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | The University of Kansas (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006023704-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | UNIVERSITY OF KANSAS (US) | 2006-03-02 | — | — | WO | disclosed |